Companies /Healthcare

Viridian Therapeutics Inc

NASDAQ: VRDN Biotechnology
$22.43
▲ $1.63 (+7.84%) today
Markets closed · 2:32am ET

VRDN at a Glance

Valuation
Market cap
$2.4B
Profitability
Revenue (TTM)
$71.1M
EPS (TTM)
$-3.39
Price
52-week range
$13 – $34
Street target
$36.75
Earnings
Next report
Nov 4, 2026

Headquartered in Waltham, MA Fiscal year ends December NASDAQ: VRDN viridiantherapeutics.com

About Viridian Therapeutics

Viridian Therapeutics is a commercial-stage biotechnology company focused on discovering, developing, and commercializing medicines for autoimmune and rare diseases. The company utilizes expertise in antibody discovery and protein engineering to build on proven science. Its commercial product, Lumvoa (veligrotug-vvze), is an FDA-approved full IGF-1R antagonist for the treatment of thyroid eye disease (TED). Viridian is also advancing elegrobart, a late-stage investigational subcutaneous therapy designed as a self-administered autoinjector for TED. Beyond TED, the company is developing a pipeline including an anti-TSHR antibody program for TED and Graves' disease, as well as FcRn inhibitor candidates (VRDN-008 and VRDN-006) targeting multiple serious autoimmune diseases. The company trades on Nasdaq under the ticker VRDN. Updated

VRDN Coverage

Frequently Asked Questions

What does Viridian Therapeutics do?

Viridian Therapeutics is a commercial-stage biotechnology company focused on discovering, developing, and commercializing medicines for autoimmune and rare diseases. The company utilizes expertise in antibody discovery and protein engineering to build on proven science.

What is the VRDN stock price target?

The Wall Street consensus 12-month price target for VRDN is $36.75.